Cyclooxygenase inhibitors and cardiovascular risk.
Andersohn
Frank
F
Suissa
Samy
S
Garbe
Edeltraut
E
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000378:metabolism; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000235:genetics; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects* / Q000378:metabolism; D012306:Risk; D013449:Sulfonamides / Q000009:adverse effects* / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D000068579:Celecoxib